Read by QxMD icon Read

Pharmacogenetics and Genomics

Frederik Vandenberghe, Núria Saigí-Morgui, Aurélie Delacrétaz, Lina Quteineh, Séverine Crettol, Nicolas Ansermot, Mehdi Gholam-Rezaee, Armin von Gunten, Philippe Conus, Chin B Eap
BACKGROUND: Psychotropic drugs can induce significant (>5%) weight gain (WG) already after 1 month of treatment, which is a good predictor for major WG at 3 and 12 months. The large interindividual variability of drug-induced WG can be explained in part by genetic and clinical factors. AIM: The aim of this study was to determine whether extensive analysis of genes, in addition to clinical factors, can improve prediction of patients at risk for more than 5% WG at 1 month of treatment...
October 12, 2016: Pharmacogenetics and Genomics
Sijia Yan, Sheng-An Chen, Wen Zhang, Fanping Yang, Ying Yang, Qinyuan Zhu, Huizhong Zhu, Xinfen Sun, Menglin Jiang, Yu Su, Lirong Zhang, Qinghe Xing, Xiaoqun Luo
OBJECTIVE: Tetanus antitoxin (TAT) is an effective antitetanus medicine, but may sometimes cause adverse drug reactions such as rapid-onset anaphylactic shock and late-onset cutaneous adverse drug reactions, including exanthematous drug eruptions (EDE). Human leukocyte antigen (HLA) class I alleles are strongly associated with different types of cutaneous adverse drug reactions. This study aimed to assess whether there is an association between TAT-induced EDE and HLA-A, HLA-B, and HLA-C alleles in the Chinese Han population...
October 5, 2016: Pharmacogenetics and Genomics
Liang Li, Jian-Wei Zhang, Gregory Jenkins, Fang Xie, Erin E Carlson, Brooke L Fridley, William R Bamlet, Gloria M Petersen, Robert R McWilliams, Liewei Wang
BACKGROUND: Pancreatic cancer is a rapidly fatal disease with gemcitabine remaining the first-line therapy. We performed a genotype-phenotype association study to identify biomarkers for predicting gemcitabine treatment outcome. MATERIALS AND METHODS: We selected the top 200 single nucleotide polymorphisms (SNPs) identified from our previous genome-wide association study to associate with overall survival using 400 patients treated with/or without gemcitabine, followed by imputation analysis for regions around the identified SNPs and a replication study using an additional 537 patients by the TaqMan genotyping assay...
October 4, 2016: Pharmacogenetics and Genomics
Julia M Barbarino, Tracy L McGregor, Russ B Altman, Teri E Klein
No abstract text is available yet for this article.
September 20, 2016: Pharmacogenetics and Genomics
Alison E Fohner, Ellen M McDonagh, John P Clancy, Michelle Whirl Carrillo, Russ B Altman, Teri E Klein
No abstract text is available yet for this article.
September 15, 2016: Pharmacogenetics and Genomics
Sergi Mas, Ana Blázquez, Natalia Rodríguez, Daniel Boloc, Amalia Lafuente, Joan A Arnaiz, Luisa Lázaro, Patricia Gassó
OBJECTIVE: Pharmacogenetic studies of fluoxetine in children and adolescents are scarce. After reporting the effect of genetic variants in genes related to the fluoxetine pharmacokinetics on clinical response in a pediatric population, we now evaluate the impact of genetic markers involved in its pharmacodynamics. PATIENTS AND METHODS: The assessment was performed in 83 patients after 12 weeks of fluoxetine treatment. The genetic association analysis included a total of 316 validated single nucleotide polymorphisms in 45 candidate genes involved in six different pathways...
November 2016: Pharmacogenetics and Genomics
Leire Iparraguirre, Angela Gutierrez-Camino, Maitane Umerez, Idoia Martin-Guerrero, Itziar Astigarraga, Aurora Navajas, Ana Sastre, Nagore Garcia de Andoin, Africa Garcia-Orad
OBJECTIVES: Methotrexate (MTX), the key drug in childhood B-cell acute lymphoblastic leukemia (B-ALL) therapy, often causes toxicity. An association between genetic variants in MTX transport genes and toxicity has been found. It is known that these transporters are regulated by microRNAs (miRNAs), and miRNA single nucleotide polymorphisms (SNPs) interfere with miRNA levels or function. With regard to B-cell ALL, we have previously found rs56103835 in miR-323b that targets ABCC4 associated with MTX plasma levels...
November 2016: Pharmacogenetics and Genomics
Otito F Iwuchukwu, Andrea H Ramirez, Yaping Shi, Erica A Bowton, Vivian K Kawai, Jonathan S Schildcrout, Dan M Roden, Joshua C Denny, C Michael Stein
OBJECTIVES: Genetic factors contribute considerably toward variability in warfarin dose requirements and are important in the dose-titration phase; their effects on the stability of anticoagulation later in therapy are not known. METHODS: Using deidentified electronic medical records linked to a DNA-biobank, we studied 140 African-Americans and 943 European-Americans after the warfarin dose-titration phase. We genotyped 12 single nucleotide polymorphisms in genes (CYP2C9, VKORC1, CYP4F2, GGCX, EPHX1, CALU) associated with altered warfarin dose requirements and tested their associations with international normalized ratio variability (INRVAR) and percent time in therapeutic range in European-Americans and African-Americans...
November 2016: Pharmacogenetics and Genomics
Feng Jiang, Han Yan, Chong Wu, Chun Song, Bin Zhao, Yang Li, Jie Dong, Gu-Yan Zheng, Li-Juan Jin, Xue-Qi Li, Wei-Yang Li, Jun Cai, Xin-Chun Yang, Xiao-Li Tian
OBJECTIVE: The aim of this study was to refine the chromosomal region 12q24.1 associated with coronary artery disease in Han Chinese populations. METHODS AND RESULTS: Twenty tagging single nucleotide polymorphisms covering 1.2 Mb of chromosomal 12q24.1 were selected and genotyped in three geographically isolated case-control populations consisting of 7076 coronary artery disease (CAD) patients and non-CAD participants. In addition to replication of the previous block (block 1), we identified a novel block (block 2) associated with CAD...
November 2016: Pharmacogenetics and Genomics
Immaculate M Langmia, Yamunah D Apalasamy, Siti Z Omar, Zahurin Mohamed
OBJECTIVE: Genetic factors influence susceptibility to preterm birth (PTB) and the immune pathway of PTB that involves the production of cytokines such as interleukins has been implicated in PTB disease. The aim of this study is to investigate the association of interleukin 1β (IL1B) gene polymorphisms and IL1B levels with spontaneous PTB. STUDY DESIGN: Peripheral maternal blood from 495 women was used for extraction of DNA and genotyping was carried out using the Sequenom MassARRAY platform...
November 2016: Pharmacogenetics and Genomics
Paul Leger, Sanika Chirwa, Megan Turner, Danielle M Richardson, Paxton Baker, Michael Leonard, Husamettin Erdem, Lana Olson, David W Haas
BACKGROUND: Efavirenz frequently causes central nervous system (CNS) symptoms. We evaluated genetic associations with efavirenz discontinuation for CNS symptoms within 12 months of treatment initiation. METHODS: Patients had initiated efavirenz-containing regimens at an HIV primary care clinic in the Southeastern United States and had at least 12 months of follow-up data. Polymorphisms in CYP2B6 and CYP2A6 defined efavirenz metabolizer categories. Genome-wide genotyping enabled adjustment for population stratification...
October 2016: Pharmacogenetics and Genomics
Kosuke Doki, Yukio Sekiguchi, Keisuke Kuga, Kazutaka Aonuma, Masato Homma
OBJECTIVE: β1-Adrenergic receptor (β1-AR) stimulation modulates the antiarrhythmic activities of sodium channel blockers. The β1-AR Gly389 variant shows a marked decrease in agonist-stimulated cyclic AMP production compared with that of the wild-type Arg389 in vitro. We investigated whether the Arg389Gly polymorphism affects the efficacy of flecainide, a typical sodium channel blocker, in patients with or without coadministration of β-blockers. METHODS: The effects of the β1-AR Arg389Gly polymorphism on the antiarrhythmic efficacy of flecainide were compared between with and without coadministered β-blockers in 159 patients with supraventricular tachyarrhythmia...
October 2016: Pharmacogenetics and Genomics
Fabiana D V Genvigir, Patricia C Salgado, Claudia R Felipe, Elena Y F Luo, Camila Alves, Alvaro Cerda, Helio Tedesco-Silva, Jose O Medina-Pestana, Nagilla Oliveira, Alice C Rodrigues, Sonia Q Doi, Mario H Hirata, Rosario D C Hirata
BACKGROUND: Polymorphisms in genes encoding transport proteins and metabolizing enzymes involved in tacrolimus (TAC) disposition may be important sources of individual variability during treatment. OBJECTIVE: The aim of this study was to investigate the effect of combined CYP3A4 and CYP3A5 variants, using a CYP3A4/5 genetic score, and ABCB1 polymorphisms on therapeutic TAC monitoring and their relationship with clinical outcomes. MATERIAL AND METHODS: Brazilian kidney transplant recipients (n=151), who received TAC over 3 months after transplantation, were genotyped for CYP3A4 rs2242480 (g...
October 2016: Pharmacogenetics and Genomics
Benjamin C Lewis, Porntipa Korprasertthaworn, John O Miners
OBJECTIVES: To extend our understanding of how interindividual variability mediates the efficacy of cancer treatment. MATERIALS AND METHODS: The kinetics of dacarbazine (DTIC) N-demethylation by the most frequent polymorphic variants of CYP1A1 (T461N, I462V) and CYP1A2 (F186L, D348N, I386F, R431W, R456H) were characterized, along with kinetic parameters for the O-deethylation of the prototypic CYP1A substrate 7-ethoxyresorufin, using recombinant protein expression and high-performance liquid chromatographic techniques...
October 2016: Pharmacogenetics and Genomics
Benjamin French, Le Wang, Brian F Gage, Richard B Horenstein, Nita A Limdi, Stephen E Kimmel
OBJECTIVE: Randomized trials have reported inconsistent evidence on the effectiveness of algorithms that use genotypes to initiate warfarin therapy. The Clarification of Optimal Anticoagulation through Genetics (COAG) trial initiated therapy on the basis of predicted maintenance doses, with a pharmacogenetic-guided algorithm in one study group and a clinically guided algorithm in the other. The European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) consortium initiated therapy on the basis of loading doses, with an algorithm-based prediction in one study group and a fixed-dose regimen in the other...
October 2016: Pharmacogenetics and Genomics
Daryl Shorter, David A Nielsen, Sara C Hamon, Ellen M Nielsen, Thomas R Kosten, Thomas F Newton, Richard De La Garza
OBJECTIVES: We examined whether a functional variant of the ADRA1A gene moderated cocaine-induced subjective effects in a group of cocaine-dependent individuals. METHODS: This study was a within-participant, double-blind, placebo-controlled inpatient human laboratory evaluation of 65 nontreatment-seeking, cocaine-dependent [Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV)] individuals aged 18-55 years. Participants received both placebo (saline, IV) and cocaine (40 mg, IV), and subjective responses were assessed 15 min before receiving an infusion and at 5 min intervals for the subsequent 20 min...
September 2016: Pharmacogenetics and Genomics
Giacomo Caldarola, Alessandro Sgambato, Caterina Fanali, Gaia Moretta, Marisa Farina, Donatella Lucchetti, Ketty Peris, Clara De Simone
OBJECTIVE: This retrospective study aimed to evaluate the role of NFKB1-94 insertion/deletion ATTG (rs28362491) and NFkBIA 2758 A>G (rs696) polymorphisms and HLA-Cw6 allele in predicting the response to etanercept, a TNF-α blocker, in a population of psoriatic patients naive to biologics. METHODS: Genomic DNA was extracted from whole blood in a series of 96 psoriatic patients who received etanercept for at least 3 months. Patients were classified as responders if they achieved a Psoriasis Area and Severity Index improvement of at least 75% after 12 weeks of etanercept treatment and as nonresponders if Psoriasis Area and Severity Index improvement was less than 75%...
September 2016: Pharmacogenetics and Genomics
Daniel J Klein, Sotiria Boukouvala, Ellen M McDonagh, Scott R Shuldiner, Nicola Laurieri, Caroline F Thorn, Russ B Altman, Teri E Klein
No abstract text is available yet for this article.
September 2016: Pharmacogenetics and Genomics
Camilla Stephens, Agustin Castiella, Eva M Gomez-Moreno, Pedro Otazua, Miguel-Ángel López-Nevot, Eva Zapata, Aida Ortega-Alonso, Francisco Ruiz-Cabello, Inmaculada Medina-Cáliz, Mercedes Robles-Díaz, German Soriano, Eva Roman, Hacibe Hallal, José M Moreno-Planas, Martin Prieto, Raúl J Andrade, M Isabel Lucena
OBJECTIVES: Positive autoantibody (AAB) titres are commonly encountered in autoimmune hepatitis (AIH) and in a proportion of drug-induced liver injury (DILI) patients. The underlying mechanism for selective AAB occurrence in DILI is unknown, but could be associated with variations in immune-associated genes. Hence, we aimed to analyse human leucocyte antigen (HLA) allele compositions in DILI with positive (+) and negative (-) AAB titres and in AIH patients. METHODS: High-resolution genotyping of HLA class I (A, B, C) and II (DRB1, DQB1) loci was performed on 207 DILI and 50 idiopathic AIH patients and compared with 885 healthy Spanish controls...
September 2016: Pharmacogenetics and Genomics
Miki Nishimura, Mikito Ueda, Junji Saruwatari, Hiroo Nakashima, Naoki Ogusu, Akiko Aoki, Shoko Tsuchimine, Kazuki Matsuda, Kazuma Iwashita, Tatsumasa Ono, Kentaro Oniki, Kazutaka Shimoda, Norio Yasui-Furukori
OBJECTIVE: Although the reduced function of the cytochrome P450 2D6*10 (CYP2D6*10) allele is common among Asian populations, existing evidence does not support paroxetine therapy adjustments for patients who have the CYP2D6*10 allele. In this study, we attempted to evaluate the degree of the impact of different CYP2D6 genotypes on the pharmacokinetic (PK) variability of paroxetine in a Japanese population using a population PK approach. METHODS: This retrospective study included 179 Japanese patients with major depressive disorder who were being treated with paroxetine...
September 2016: Pharmacogenetics and Genomics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"